The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosis

Antioxidants and Redox Signaling

Volumn 10, Issue 2, 2008, Pages 287-301

  Bringardner, Benjamin D ^a   Baran, Christopher P ^a   Eubank, Timothy D ^a   Marsh, Clay B ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTACOID; CYTOKINE; GROWTH FACTOR; GROWTH FACTOR RECEPTOR;

CELL INFILTRATION; DISEASE COURSE; DISEASE MODEL; FIBROBLAST; FIBROSING ALVEOLITIS; HUMAN; HYPOTHESIS; INFLAMMATION; INFLAMMATORY CELL; LUNG BLOOD FLOW; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; REVIEW;

ANIMALS; ASBESTOS; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; LUNG; MODELS, BIOLOGICAL; PULMONARY CIRCULATION; PULMONARY FIBROSIS; SMOKING;

EID: 37549060626     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2007.1897     Document Type: Review

References (159)

1. American Thoracic Society Committee of the Scientific Assembly on Environmental and Occupational Health. Adverse effects of crystalline silica exposure. Am J Respir Crit Care Med 155: 761-768, 1997.
2. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment: international consensus statement: American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 161: 646-664, 2000.
3. American Thoracic Society/European Respiratory Society. International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias: this joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS Board of Directors, June 2001 and by The ERS Executive Committee, June 2001. Am J Respir Crit Care Med 165: 277-304, 2002.
4. Adamson IY. Drug-induced pulmonary fibrosis. Environ Health Perspect 55: 25-36, 1984.
5. Adamson IY. Pulmonary toxicity of bleomycin. Environ Health Perspect 16: 119-125, 1976.
6. Adamson IY and Bowden DH. The pathogenesis of bleomycininduced pulmonary fibrosis in mice. Am J Pathol 77: 185-197, 1974.
7. Adamson IY and Bowden DH. Role of polymorphonuclear leukocytes in silica-induced pulmonary fibrosis. Am J Pathol 117: 37-43, 1984.
8. Al-Motabagani MA. Histological changes in the alveolar structure of the rat lung after exposure to hyperoxia. Ital J Anat Embryol 110: 209-223, 2005.
9. Antoniades HN, Bravo MA, Avila RE, Galanopoulos T, Neville-Golden J, Maxwell M, and Selman M. Platelet-derived growth factor in idiopathic pulmonary fibrosis. J Clin Invest 86: 1055-1064, 1990.
10. Antoniou KM, Tzouvelekis A, Alexandrakis MG, Sfiridaki K, Tsiligianni I, Rachiotis G, Tzanakis N, Bouros D, Milic-Emili J, and Siafakas NM. Different angiogenic activity in pulmonary sarcoidosis and idiopathic pulmonary fibrosis. Chest 130: 982-988, 2006.
11. Arbetter KR, Prakash UB, Tazelaar HD, and Douglas WW. Radiation-induced pneumonitis in the "nonirradiated" lung. Mayo Clin Proc 74: 27-36, 1999.
12. Armanios MY, Chen JJ, Cogan JD, Alder JK, Ingersoll RG, Markin C, Lawson WE, Xie M, Vulto I, Phillips JA, 3rd, Lansdorp PM, Greider CW, and Loyd JE. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 356: 1317-1326, 2007.
13. Baran CP, Opalek JM, McMaken S, Newland CA, O'Brien JM Jr, Hunter MG, Bringardner BD, Monick MM, Brigstock DR, Stromberg PC, Hunninghake GW, and Marsh CB. Important roles for M-CSF, CCL2 and mononuclear phagocytes in the pathogenesis of pulmonary fibrosis. Am J Respir Crit Care Med 176: 78-89, 2007.
14. Beeh KM, Beier J, Kornmann O, and Buhl R. Neutrophilic inflammation in induced sputum of patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 20: 138-143, 2003.
15. Behr J, Maier K, Degenkolb B, Krombach F, and Vogelmeier C. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis: adjunctive therapy to maintenance immunosuppression. Am J Respir Crit Care Med 156: 1897-1901, 1997.
16. Beon M, Harley RA, Wessels A, Silver RM, and Ludwicka-Bradley A. Myofibroblast induction and microvascular alteration in scleroderma lung fibrosis. Clin Exp Rheumatol 22: 733-742, 2004.
17. Bhatt NY, Kelley TW, Khramtsov VV, Wang Y, Lam GK, Clanton TL, and Marsh CB. Macrophage-colony-stimulating factor-induced activation of extracellular-regulated kinase involves phosphatidylinositol 3-kinase and reactive oxygen species in human monocytes. J Immunol 169: 6427-6434, 2002.
18. Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR, and Offord KP. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 157: 199-203, 1998.
19. Blom IE, Goldschmeding R, and Leask A. Gene regulation of connective tissue growth factor: new targets for antifibrotic therapy? Matrix Biol 21: 473-482, 2002.
20. Borges VM, Falcao H, Leite-Junior JH, Alvim L, Teixeira GP, Russo M, Nobrega AF, Lopes MF, Rocco PM, Davidson WF, Linden R, Yagita H, Zin WA, and DosReis GA. Fas ligand triggers pulmonary silicosis. J Exp Med 194: 155-164, 2001.
21. Bowden DH and Adamson IY. The role of cell injury and the continuing inflammatory response in the generation of silicotic pulmonary fibrosis. J Pathol 144: 149-161, 1984.
22. Bowden DH, Hedgecock C, and Adamson IY. Silica-induced pulmonary fibrosis involves the reaction of particles with interstitial rather than alveolar macrophages. J Pathol 158: 73-80, 1989.
23. Bozelka BE, Sestini P, Gaumer HR, Hammad Y, Heather CJ, and Salvaggio JE. A murine model of asbestosis. Am J Pathol 112: 326-337, 1983.
24. Brigstock DR. Regulation of angiogenesis and endothelial cell function by connective tissue growth factor (CTGF) and cysteine-rich 61 (CYR61). Angiogenesis 5: 153-165, 2002.
25. Brody AR, Hill LH, Adkins B Jr, and O'Connor RW. Chrysotile asbestos inhalation in rats: deposition pattern and reaction of alveolar epithelium and pulmonary macrophages. Am Rev Respir Dis 123: 670-679, 1981.
26. Brown JM, Swindle EJ, Kushnir-Sukhov NM, Holian A, and Metcalfe DD. Silica-directed mast cell activation is enhanced by scavenger receptors. Am J Respir Cell Mol Biol 36: 43-52, 2007.
27. Car BD, Meloni F, Luisetti M, Semenzato G, Gialdroni-Grassi G, and Walz A. Elevated IL-8 and MCP-1 in the bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am J Respir Crit Care Med 149: 655-659, 1994.
28. Cavanagh LL, Saal RJ, Grimmett KL, and Thomas R. Proliferation in monocyte-derived dendritic cell cultures is caused by progenitor cells capable of myeloid differentiation. Blood 92: 1598-1607, 1998.
29. Chambers SK, Gilmore-Hebert M, Wang Y, Rodov S, Benz EJ Jr, and Kacinski BM. Posttranscriptional regulation of colony-stimulating factor-1 (CSF-1) and CSF-1 receptor gene expression during inhibition of phorbol-ester-induced monocytic differentiation by dexamethasone and cyclosporin A: potential involvement of a destabilizing protein. Exp Hematol 21: 1328-1334, 1993.
30. Chua F, Gauldie J, and Laurent GJ. Pulmonary fibrosis: searching for model answers. Am J Respir Cell Mol Biol 33: 9-13, 2005.
31. Churg A, Muller NL, Silva CI, and Wright JL. Acute exacerbation (acute lung injury of unknown cause) in UIP and other forms of fibrotic interstitial pneumonias. Am J Surg Pathol 31: 277-284, 2007.
32. Cisneros-Lira J, Gaxiola M, Ramos C, Selman M, and Pardo A. Cigarette smoke exposure potentiates bleomycin-induced lung fibrosis in guinea pigs. Am J Physiol Lung Cell Mol Physiol 285: L949-L956, 2003.
33. Coggle JE, Lambert BE, and Moores SR. Radiation effects in the lung. Environ Health Perspect 70: 261-291, 1986.
34. Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King Jr TE, Lasky JA, Lloyd JE, Noth I, Olman MA, Raghu G, Roman J, Ryu JH, Zisman DA, Hunnighake GW, Colby TV, Egan JJ, Hansell DM, Johkoh T, and Martinez FJ. Pulmonary perspective: acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 176: 636-643, 2007.
35. Cummins AB, Palmer C, Mossman BT, and Taatjes DJ. Persistent localization of activated extracellular signal-regulated kinases (ERK1/2) is epithelial cell-specific in an inhalation model of asbestosis. Am J Pathol 162: 713-720, 2003.
36. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, MacNee W, Thomeer M, Wallaert B, Laurent F, Nicholson AG, Verbeken EK, Verschakelen J, Flower CD, Capron F, Petruzzelli S, De Vuyst P, van den Bosch JM, Rodriguez-Becerra E, Corvasce G, Lankhorst I, Sardina M, and Montanari M. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 353: 2229-2242, 2005.
37. Diaz-Romero J, Gaillard JP, Grogan SP, Nesic D, Trub T, and Mainil-Varlet P. Immunophenotypic analysis of human articular chondrocytes: changes in surface markers associated with cell expansion in monolayer culture. J Cell Physiol 202: 731-742, 2005.
38. Elliott CG, Rasmusson BY, Crapo RO, Morris AH, and Jensen RL. Prediction of pulmonary function abnormalities after adult respiratory distress syndrome (ARDS). Am Rev Respir Dis 135: 634-638, 1987.
39. Entzian P, Gerlach C, Gerdes J, Schlaak M, and Zabel P. [Pentoxifylline inhibits experimental bleomycin-induced fibrosing alveolitis]. Pneumologie 51: 375-380, 1997.
40. Fay M, Tan A, Fisher R, Mac Manus M, Wirth A, and Ball D. Dose-volume histogram analysis as predictor of radiation pneumonitis in primary lung cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 61: 1355-1363, 2005.
41. Flaherty KR, Andrei A-C, King TE Jr, Raghu G, Colby TV, Wells A, Bassily N, Brown K, du Bois R, Flint A, Gay SE, Gross BH, Kazerooni EA, Knapp R, Louvar E, Lynch D, Nicholson AG, Quick J, Thannickal VJ, Travis WD, Vyskocil J, Wadenstorer FA, Wilt J, Toews GB, Murray S, and Martinez FJ. Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis? Am J Respir Crit Care Med 175: 1054-1060, 2007.
42. Flaherty KR, Toews GB, Travis WD, Colby TV, Kazerooni EA, Gross BH, Jain A, Strawderman RL, III, Paine R, Flint A, Lynch JP, III, and Martinez FJ. Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur Respir J 19: 275-283, 2002.
43. Flaherty KR, Travis WD, Colby TV, Toews GB, Kazerooni EA, Gross BH, Jain A, Strawderman RL, Flint A, Lynch JP, and Martinez FJ. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med 164: 1722-1727, 2001.
44. Fowlkes JL and Winkler MK. Exploring the interface between metallo-proteinase activity and growth factor and cytokine bioavailability. Cytokine Growth Factor Rev 13: 277-287, 2002.
45. Freeman BA and Crapo JD. Hyperoxia increases oxygen radical production in rat lungs and lung mitochondria. J Biol Chem 256: 10986-10992, 1981.
46. Furuie H, Yamasaki H, Suga M, and Ando M. Altered accessory cell function of alveolar macrophages: a possible mechanism for induction of Th2 secretory profile in idiopathic pulmonary fibrosis. Eur Respir J 10: 787-794, 1997.
47. Garcia-Alvarez J, Ramirez R, Sampieri CL, Nuttall RK, Edwards DR, Selman M, and Pardo A. Membrane type-matrix metalloproteinases in idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 23: 13-21, 2006.
48. Gauldie J. Pro: Inflammatory mechanisms are a minor component of the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 165: 1205-1206, 2002.
49. Gauldie J, Kolb M, Ask K, Martin G, Bonniaud P, and Warburton D. Smad3 signaling involved in pulmonary fibrosis and emphysema. Proc Am Thorac Soc 3: 696-702, 2006.
50. Gelrud LG, Arseneau JC, Milder MS, Kramer RJ, Swann SJ, Canellos GP, and Johnston GS. The kinetics of 67gallium incorporation into inflammatory lesions: experimental and clinical studies. J Lab Clin Med 83: 489-495, 1974.
51. Giorgino F and Smith RJ. Dexamethasone enhances insulin-like growth factor-I effects on skeletal muscle cell proliferation: role of specific intracellular signaling pathways. J Clin Invest 96: 1473-1483, 1995.
52. 67Ga scintigraphy as an indicator of response to and prognosis after corticosteroid treatment in idiopathic interstitial pneumonia. J Nucl Med 46: 1421-1426, 2005.
53. Gross NJ, Narine KR, and Wade R. Protective effect of corticosteroids on radiation pneumonitis in mice. Radiat Res 113: 112-119, 1988.
54. Gross TJ and Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med 345: 517-525, 2001.
55. Hallgren R, Bjermer L, Lundgren R, and Venge P. The eosinophil component of the alveolitis in idiopathic pulmonary fibrosis: signs of eosinophil activation in the lung are related to impaired lung function. Am Rev Respir Dis 139: 373-377, 1989.
56. Hammann LRA. Acute diffuse interstitial fibrosis of the lungs. Bull Johns Hopkins Hosp 74: 177-212, 1944.
57. Hammond EC, Selikoff IJ, and Seidman H. Asbestos exposure, cigarette smoking and death rates. Ann N Y Acad Sci 330: 473-490, 1979.
58. Hattori N, Degen JL, Sisson TH, Liu H, Moore BB, Pandrangi RG, Simon RH, and Drew AF. Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice. J Clin Invest 106: 1341-1350, 2000.
59. Hidalgo A, Franquet T, Gimenez A, Bordes R, Pineda R, and Madrid M. Smoking-related interstitial lung diseases: radiologicpathologic correlation. Eur Radiol 16: 2463-2470, 2006.
60. Hiwatari N, Shimura S, Sasaki T, Aikawa T, Ando Y, Ishihara H, Sekizawa K, Sasaki H, and Takishima T. Prognosis of idiopathic pulmonary fibrosis in patients with mucous hypersecretion. Am Rev Respir Dis 143: 182-185, 1991.
61. Hiwatari N, Shimura S, Takishima T, and Shirato K. Bronchoalveolar lavage as a possible cause of acute exacerbation in idiopathic pulmonary fibrosis patients. Tohoku J Exp Med 174: 379-386, 1994.
62. Huaux F, Louahed J, Hudspith B, Meredith C, Delos M, Renauld JC, and Lison D. Role of interleukin-10 in the lung response to silica in mice. Am J Respir Cell Mol Biol 18: 51-59, 1998.
63. Hunninghake GW, Gadek JE, Lawley TJ, and Crystal RG. Mechanisms of neutrophil accumulation in the lungs of patients with idiopathic pulmonary fibrosis. J Clin Invest 68: 259-269, 1981.
64. Igarashi A, Bradham DM, Okochi H, and Grotendorst GR. Connective tissue growth factor. J Dermatol 19: 642-643, 1992.
65. Igarashi A, Okochi H, Bradham DM, and Grotendorst GR. Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair. Mol Biol Cell 4: 637-645, 1993.
66. Ihn H, Sato S, Fujimoto M, Igarashi A, Yazawa N, Kubo M, Kikuchi K, Takehara K, and Tamaki K. Characterization of autoantibodies to endothelial cells in systemic sclerosis (SSc): association with pulmonary fibrosis. Clin Exp Immunol 119: 203-209, 2000.
67. Inaba T, Yamada N, Gotoda T, Shimano H, Shimada M, Momomura K, Kadowaki T, Motoyoshi K, Tsukada T, Morisaki N, Morisaki N, Yasushi S, Yoshida S, Takaku F, and Yazaki Y. Expression of M-CSF receptor encoded by c-fms on smooth muscle cells derived from arteriosclerotic lesion. J Biol Chem 267: 5693-5699, 1992.
68. Jakubzick C, Choi ES, Kunkel SL, Evanoff H, Martinez FJ, Puri RK, Flaherty KR, Toews GB, Colby TV, Kazerooni EA, Gross BH, Travis WD, and Hogaboam CM. Augmented pulmonary IL-4 and IL-13 receptor subunit expression in idiopathic interstitial pneumonia. J Clin Pathol 57: 477-486, 2004.
69. Janssen YM, Marsh JP, Absher M, Borm PJ, and Mossman BT. Increases in endogenous antioxidant enzymes during asbestos inhalation in rats. Free Radic Res Commun 11: 53-58, 1990.
70. Jiao A, Fish SC, Mason LE, Schelling SH, Goldman SJ, and Williams CM. A role for endothelial selectins in allergic and nonallergic inflammatory disease. Ann Allergy Asthma Immunol 98: 83-88, 2007.
71. Johnston CJ, Williams JP, Elder A, Hernady E, and Finkelstein JN. Inflammatory cell recruitment following thoracic irradiation. Exp Lung Res 30: 369-382, 2004.
72. Jones AW and Reeve NL. Ultrastructural study of bleomycin-induced pulmonary changes in mice. J Pathol 124: 227-233, 1978.
73. Kasai H, Allen JT, Mason RM, Kamimura T, and Zhang Z. TGFbeta1 induces human alveolar epithelial to mesenchymal cell transition (EMT). Respir Res 6: 56, 2005.
74. Katzenstein AL and Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 157: 1301-1315, 1998.
75. Keane J, Gochuico B, Kasznica JM, and Kornfeld H. Usual interstitial pneumonitis responsive to corticosteroids following varicella pneumonia. Chest 113: 249-251, 1998.
76. Keogh KA and Limper AH. Characterization of lymphocyte populations in nonspecific interstitial pneumonia. Respir Res 6: 137, 2005.
77. Khazen W, M'Bika J P, Tomkiewicz C, Benelli C, Chany C, Achour A, and Forest C. Expression of macrophage-selective markers in human and rodent adipocytes. FEBS Lett 579: 5631-5634, 2005.
78. Kim DS, Collard HR, and King TE Jr. Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc 3: 285-292, 2006.
79. Kim KK, Kugler MC, Wolters PJ, Robillard L, Galvez MG, Brumwell AN, Sheppard D, and Chapman HA. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci U S A 103: 13180-13185, 2006.
80. Kim TH, Cho KH, Pyo HR, Lee JS, Zo JI, Lee DH, Lee JM, Kim HY, Hwangbo B, Park SY, Kim JY, Shin KH, and Kim DY. Dose-volumetric parameters for predicting severe radiation pneumonitis after three-dimensional conformal radiation therapy for lung cancer. Radiology 235: 208-215, 2005.
81. Kinnula VL and Crapo JD. Superoxide dismutases in the lung and human lung diseases. Am J Respir Crit Care Med 167: 1600-1619, 2003.
82. Kinnula VL, Fattman CL, Tan RJ, and Oury TD. Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy. Am J Respir Crit Care Med 172: 417-422, 2005.
83. Kolb M, Margetts PJ, Sime PJ, and Gauldie J. Proteoglycans decorin and biglycan differentially modulate TGF-beta-mediated fibrotic responses in the lung. Am J Physiol Lung Cell Mol Physiol 280: L1327-L1334, 2001.
84. Kondoh Y, Taniguchi H, Kitaichi M, Yokoi T, Johkoh T, Oishi T, Kimura T, Nishiyama O, Kato K, and du Bois RM. Acute exacerbation of interstitial pneumonia following surgical lung biopsy. Respir Med 100: 1753-1759, 2006.
85. Kremer S, Breuer R, Lossos IS, Berkman N, Christensen TG, Connor MW, Goldstein RH, and Or R. Effect of immunomodulators on bleomycin-induced lung injury. Respiration 66: 455-462, 1999.
86. Kubo H, Nakayama K, Yanai M, Suzuki T, Yamaya M, Watanabe M, and Sasaki H. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 128: 1475-1482, 2005.
87. Lakatos HF, Burgess HA, Thatcher TH, Redonnet MR, Hernady E, Williams JP, and Sime PJ. Oropharyngeal aspiration of a silica suspension produces a superior model of silicosis in the mouse when compared to intratracheal instillation. Exp Lung Res 32: 181-199, 2006.
88. Leask A and Abraham DJ. The role of connective tissue growth factor, a multifunctional matricellular protein, in fibroblast biology. Biochem Cell Biol 81: 355-363, 2003.
89. Liu JY, Brass DM, Hoyle GW, and Brody AR. TNF-alpha receptor knockout mice are protected from the fibroproliferative effects of inhaled asbestos fibers. Am J Pathol 153: 1839-1847, 1998.
90. Liu JY and Brody AR. Increased TGF-beta1 in the lungs of asbestos-exposed rats and mice: reduced expression in TNF-alpha receptor knockout mice. J Environ Pathol Toxicol Oncol 20: 97-108, 2001.
91. Luna MA, Bedrossian CW, Lichtiger B, and Salem PA. Interstitial pneumonitis associated with bleomycin therapy. Am J Clin Pathol 58: 501-510, 1972.
92. Magro CM, Morrison C, Pope-Harman A, Rothrauff SK, and Ross P Jr. Direct and indirect immunofluorescence as a diagnostic adjunct in the interpretation of nonneoplastic medical lung disease. Am J Clin Pathol 119: 279-289, 2003.
93. Magro CM, Waldman WJ, Knight DA, Allen JN, Nadasdy T, Frambach GE, Ross P, and Marsh CB. Idiopathic pulmonary fibrosis related to endothelial injury and antiendothelial cell antibodies. Hum Immunol 67: 284-297, 2006.
94. Magro CM, Wusirika R, Frambach GE, Nuovo GJ, Ferri C, and Ross P Jr. Autoimmune-like pulmonary disease in association with parvovirus B19: a clinical, morphologic, and molecular study of 12 cases. Appl Immunohistochem Mol Morphol 14: 208-216, 2006.
95. Manoury B, Nenan S, Guenon I, Lagente V, and Boichot E. Influence of early neutrophil depletion on MMPs/TIMP-1 balance in bleomycin-induced lung fibrosis. Int Immunopharmacol 7: 900-911, 2007.
96. Marsh CB, Gadek JE, Kindt GC, Moore SA, and Wewers MD. Monocyte Fc gamma receptor cross-linking induces IL-8 production. J Immunol 155: 3161-3167, 1995.
97. Marsh CB, Pomerantz RP, Parker JM, Winnard AV, Mazzaferri EL Jr, Moldovan N, Kelley TW, Beck E, and Wewers MD. Regulation of monocyte survival in vitro by deposited IgG: role of macrophage colony-stimulating factor. J Immunol 162: 6217-6225, 1999.
98. Marsh CB, Wewers MD, Tan LC, and Rovin BH. Fc(gamma) receptor cross-linking induces peripheral blood mononuclear cell monocyte chemoattractant protein-1 expression: role of lymphocyte Fc(gamma)RIII. J Immunol 158: 1078-1084, 1997.
99. Matsuse T, Teramoto S, Katayama H, Sudo E, Ekimoto H, Mitsuhashi H, Uejima Y, Fukuchi Y, and Ouchi Y. ICAM-1 mediates lung leukocyte recruitment but not pulmonary fibrosis in a murine model of bleomycin-induced lung injury. Eur Respir J 13: 71-77, 1999.
100. McDonald S, Rubin P, Phillips TL, and Marks LB. Injury to the lung from cancer therapy: clinical syndromes, measurable endpoints, and potential scoring systems. Int J Radiat Oncol Biol Phys 31: 1187-1203, 1995.
101. Moore BB, Murray L, Das A, Wilke CA, Herrygers AB, and Toews GB. The role of CCL12 in the recruitment of fibrocytes and lung fibrosis. Am J Respir Cell Mol Biol 35: 175-181, 2006.
102. Morla M, Busquets X, Pons J, Sauleda J, MacNee W, and Agusti AG. Telomere shortening in smokers with and without COPD. Eur Respir J 27: 525-528, 2006.
103. Mossman BT and Marsh JP. Evidence supporting a role for active oxygen species in asbestos-induced toxicity and lung disease. Environ Health Perspect 81: 91-94, 1989.
104. Movsas B, Raffin TA, Epstein AH, and Link CJ Jr. Pulmonary radiation injury. Chest 111: 1061-1076, 1997.
105. Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J, Pittet JF, Kaminski N, Garat C, Matthay MA, Rifkin DB, and Sheppard D. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 96: 319-328, 1999.
106. Nagai S, Hoshino Y, Hayashi M, and Ito I. Smoking-related interstitial lung diseases. Curr Opin Pulmon Med 6: 415-419, 2000.
107. Obayashi Y, Yamadori I, Fujita J, Yoshinouchi T, Ueda N, and Takahara J. The role of neutrophils in the pathogenesis of idiopathic pulmonary fibrosis. Chest 112: 1338-1343, 1997.
108. Ogushi F, Tani K, Maniwa K, Ichikawa W, Tada H, Kawano T, and Sone S. Interleukin-8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis or idiopathic pulmonary fibrosis. J Med Invest 44: 53-58, 1997.
109. Ohtsuka Y, Wang XT, Saito J, Ishida T, and Munakata M. Genetic linkage analysis of pulmonary fibrotic response to silica in mice. Eur Respir J 28: 1013-1019, 2006.
110. Ohtsuki T, Suzu S, Hatake K, Nagata N, Miura Y, and Motoyoshi K. A proteoglycan form of macrophage colony-stimulating factor that binds to bone-derived collagens and can be extracted from bone matrix. Biochem Biophys Res Commun 190: 215-222, 1993.
111. Osanai K, Takahashi K, Suwabe A, Takada K, Ikeda H, Sato S, and Yasui S. The effect of cigarette smoke on bleomycin-induced pulmonary fibrosis in hamsters. Am Rev Respir Dis 138: 1276-1281, 1988.
112. Ozaki T, Hayashi H, Tani K, Ogushi F, Yasuoka S, and Ogura T. Neutrophil chemotactic factors in the respiratory tract of patients with chronic airway diseases or idiopathic pulmonary fibrosis. Am Rev Respir Dis 145: 85-91, 1992.
113. Ozturk B, Egehan I, Atavci S, and Kitapci M. Pentoxifylline in prevention of radiation-induced lung toxicity in patients with breast and lung cancer: a double-blind randomized trial. Int J Radiat Oncol Biol Phys 58: 213-219, 2004.
114. Papiris SA, Kollintza A, Kitsanta P, Kapotsis G, Karatza M, Milic-Emili J, Roussos C, and Daniil Z. Relationship of BAL and lung tissue CD4+ and CD8+ T lymphocytes, and their ratio in idiopathic pulmonary fibrosis. Chest 128: 2971-2977, 2005.
115. Parambil JG, Myers JL, and Ryu JH. Histopathologic features and outcome of patients with acute exacerbation of idiopathic pulmonary fibrosis undergoing surgical lung biopsy. Chest 128: 3310-3315, 2005.
116. Parra ER, Kairalla RA, Ribeiro de Carvalho CR, Eher E, and Capelozzi VL. Inflammatory cell phenotyping of the pulmonary interstitium in idiopathic interstitial pneumonia. Respiration 74: 159-169, 2007.
117. Parvinen LM, Kilkku P, Makinen E, Liukko P, and Gronroos M. Factors affecting the pulmonary toxicity of bleomycin. Acta Radiol Oncol 22: 417-421, 1983.
118. Peterson MW, Monick M, and Hunninghake GW. Prognostic role of eosinophils in pulmonary fibrosis. Chest 92: 51-56, 1987.
119. Quinlan TR, Marsh JP, Janssen YM, Leslie KO, Hemenway D, Vacek P, and Mossman BT. Dose-responsive increases in pulmonary fibrosis after inhalation of asbestos. Am J Respir Crit Care Med 150: 200-206, 1994.
120. Rahman I, Skwarska E, Henry M, Davis M, O'Connor CM, FitzGerald MX, Greening A, and MacNee W. Systemic and pulmonary oxidative stress in idiopathic pulmonary fibrosis. Free Radic Biol Med 27: 60-68, 1999.
121. Reynolds HY. Lung inflammation and fibrosis: an alveolar macrophage-centered perspective from the 1970s to 1980s. Am J Respir Crit Care Med 171: 98-102, 2005.
122. Reynolds HY, Fulmer JD, Kazmierowski JA, Roberts WC, Frank MM, and Crystal RG. Analysis of cellular and protein content of broncho-alveolar lavage fluid from patients with idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis. J Clin Invest 59: 165-175, 1977.
123. Rimal B, Greenberg AK, and Rom WN. Basic pathogenetic mechanisms in silicosis: current understanding. Curr Opin Pulm Med 11: 169-173, 2005.
124. Robledo R and Mossman B. Cellular and molecular mechanisms of asbestos-induced fibrosis. J Cell Physiol 180: 158-166, 1999.
125. Robledo RF, Buder-Hoffmann SA, Cummins AB, Walsh ES, Taatjes DJ, and Mossman BT. Increased phosphorylated extracellular signal-regulated kinase immunoreactivity associated with proliferative and morphologic lung alterations after chrysotile asbestos inhalation in mice. Am J Pathol 156: 1307-1316, 2000.
126. Romagnani P, Annunziato F, Liotta F, Lazzeri E, Mazzinghi B, Frosali F, Cosmi L, Maggi L, Lasagni L, Scheffold A, Kruger M, Dimmeler S, Marra F, Gensini G, Maggi E, and Romagnani S. CD14+CD34 low cells with stem cell phenotypic and functional features are the major source of circulating endothelial progenitors. Circ Res 97: 314-322, 2005.
127. Rossi GA, Hunninghake GW, Kawanami O, Ferrans VJ, Hansen CT, and Crystal RG. Motheaten mice: an animal model with an inherited form of interstitial lung disease. Am Rev Respir Dis 131: 150-158, 1985.
128. Rubenstein JH, Richter MP, Moldofsky PJ, and Solin LJ. Prospective prediction of post-radiation therapy lung function using quantitative lung scans and pulmonary function testing. Int J Radiat Oncol Biol Phys 15: 83-87, 1988.
129. Ryu JH, Colby TV, and Hartman TE. Idiopathic pulmonary fibrosis: current concepts. Mayo Clin Proc 73: 1085-1101, 1998.
130. Sasmono RT, Ehrnsperger A, Cronau SL, Ravasi T, Kandane R, Hickey MJ, Cook AD, Himes SR, Hamilton JA, and Hume DA. Mouse neutrophilic granulocytes express mRNA encoding the macrophage colony-stimulating factor receptor (CSF-1R) as well as many other macrophage-specific transcripts and can transdifferentiate into macrophages in vitro in response to CSF-1. J Leukoc Biol 82: 111-123, 2007.
131. Schonherr E and Hausser HJ. Extracellular matrix and cytokines: a functional unit. Dev Immunol 7: 89-101, 2000.
132. Schuppan D, Ruehl M, Somasundaram R, and Hahn EG. Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis 21: 351-372, 2001.
133. Schwartz DA, Helmers RA, Dayton CS, Merchant RK, and Hunninghake GW. Determinants of bronchoalveolar lavage cellularity in idiopathic pulmonary fibrosis. J Appl Physiol 71: 1688-1693, 1991.
134. Selman M, Carrillo G, Estrada A, Mejia M, Becerril C, Cisneros J, Gaxiola M, Perez-Padilla R, Navarro C, Richards T, Dauber J, King TE, Pardo A, and Kaminski N. Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PLoS ONE 2: e482, 2007.
135. Shindoh Y, Shimura S, Tomioka M, Aikawa T, Sasaki H, and Takishima T. Cellular analysis in bronchoalveolar lavage fluids in infiltrative and fibrotic stages of idiopathic pulmonary fibrosis. Tohoku J Exp Med 149: 47-60, 1986.
136. Shukla A, Lounsbury KM, Barrett TF, Gell J, Rincon M, Butnor KJ, Taatjes DJ, Davis GS, Vacek P, Nakayama KI, Nakayama K, Steele C, and Mossman BT. Asbestos-induced peribronchiolar cell proliferation and cytokine production are attenuated in lungs of protein kinase C-delta knockout mice. Am J Pathol 170: 140-151, 2007.
137. Standiford TJ, Rolfe MR, Kunkel SL, Lynch JP 3rd, Becker FS, Orringer MB, Phan S, and Strieter RM. Altered production and regulation of monocyte chemoattractant protein-1 from pulmonary fibroblasts isolated from patients with idiopathic pulmonary fibrosis. Chest 103: 121S, 1993.
138. Standiford TJ, Rolfe MW, Kunkel SL, Lynch JP 3rd, Burdick MD, Gilbert AR, Orringer MB, Whyte RI, and Strieter RM. Macrophage inflammatory protein-1 alpha expression in interstitial lung disease. J Immunol 151: 2852-2863, 1993.
139. Strieter RM. Con: Inflammatory mechanisms are not a minor component of the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 165: 1206-1207; discussion 1207-1208, 2002.
140. Suh GY, Kang EH, Chung MP, Lee KS, Han J, Kitaichi M, and Kwon OJ. Early intervention can improve clinical outcome of acute interstitial pneumonia. Chest 129: 753-761, 2006.
141. Tabuena RP, Nagai S, Tsutsumi T, Handa T, Minoru T, Mikuniya T, Shigematsu M, Hamada K, Izumi T, and Mishima M. Cell profiles of bronchoalveolar lavage fluid as prognosticators of idiopathic pulmonary fibrosis/usual interstitial pneumonia among Japanese patients. Respiration 72: 490-498, 2005.
142. Taipale J and Keski-Oja J. Growth factors in the extracellular matrix. FASEB J 11: 51-59, 1997.
143. Tan RJ, Fattman CL, Niehouse LM, Tobolewski JM, Hanford LE, Li Q, Monzon FA, Parks WC, and Oury TD. Matrix metalloproteinases promote inflammation and fibrosis in asbestos-induced lung injury in mice. Am J Respir Cell Mol Biol 35: 289-297, 2006.
144. Tsakiri KD, Cronkhite JT, Kuan PJ, Xing C, Raghu G, Weissler JC, Rosenblatt RL, Shay JW, and Garcia CK. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci U S A 104: 7552-7557, 2007.
145. Uemura Y, Kobayashi M, Nakata H, Kubota T, Bandobashi K, Saito T, and Taguchi H. Effects of GM-CSF and M-CSF on tumor progression of lung cancer: roles of MEK1/ERK and AKT/PKB pathways. Int J Mol Med 18: 365-373, 2006.
146. Uh ST, Inoue Y, King TE Jr, Chan ED, Newman LS, and Riches DW. Morphometric analysis of insulin-like growth factor-I localization in lung tissues of patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 158: 1626-1635, 1998.
147. Urbich C, Heeschen C, Aicher A, Dernbach E, Zeiher AM, and Dimmeler S. Relevance of monocytic features for neovascularization capacity of circulating endothelial progenitor cells. Circulation 108: 2511-2516, 2003.
148. Vedham V, Phee H, and Coggeshall KM. Vav activation and function as a rac guanine nucleotide exchange factor in macrophage colony-stimulating factor-induced macrophage chemotaxis. Mol Cell Biol 25: 4211-4220, 2005.
149. Walter N, Collard HR, and King TE Jr. Current perspectives on the treatment of idiopathic pulmonary fibrosis. Proc Am Thorac Soc 3: 330-338, 2006.
150. Wang XM, Zhang Y, Kim HP, Zhou Z, Feghali-Bostwick CA, Liu F, Ifedigbo E, Xu X, Oury TD, Kaminski N, and Choi AM. Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis. J Exp Med 203: 2895-2906, 2006.
151. Wang Y, Zeigler MM, Lam GK, Hunter MG, Eubank TD, Khramtsov VV, Tridandapani S, Sen CK, and Marsh CB. The role of the NADPH oxidase complex, p38 MAPK, and Akt in regulating human monocyte/macrophage survival. Am J Respir Cell Mol Biol 36: 68-77, 2007.
152. Watters LC, Schwarz MI, Cherniack RM, Waldron JA, Dunn TL, Stanford RE, and King TE. Idiopathic pulmonary fibrosis: pretreatment bronchoalveolar lavage cellular constituents and their relationships with lung histopathology and clinical response to therapy. Am Rev Respir Dis 135: 696-704, 1987.
153. White B. Evaluation and management of pulmonary fibrosis in scleroderma. Curr Rheumatol Rep 4: 108-112, 2002.
154. Willis BC, Liebler JM, Luby-Phelps K, Nicholson AG, Crandall ED, du Bois RM, and Borok Z. Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. Am J Pathol 166: 1321-1332, 2005.
155. Winkler MK and Fowlkes JL. Metalloproteinase and growth factor interactions: Do they play a role in pulmonary fibrosis? Am J Physiol Lung Cell Mol Physiol 283: L1-L11, 2002.
156. Wusirika R, Ferri C, Marin M, Knight DA, Waldman WJ, Ross P Jr, and Magro CM. The assessment of anti-endothelial cell antibodies in scleroderma- associated pulmonary fibrosis: a study of indirect immunofluorescent and Western blot analysis in 49 patients with scleroderma. Am J Clin Pathol 120: 596-606, 2003.
157. Yanaba K, Komura K, Kodera M, Matsushita T, Hasegawa M, Takehara K, and Sato S. Serum levels of monocyte chemotactic protein-3/CCL7 are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. Ann Rheum Dis 65: 124-126, 2006.
158. Yasuoka S, Nakayama T, Kawano T, Ogushi F, Doi H, Hayashi H, and Tsubura E. Comparison of cell profiles of bronchial and bronchoalveolar lavage fluids between normal subjects and patients with idiopathic pulmonary fibrosis. Tohoku J Exp Med 146: 33-45, 1985.
159. Yoshida M, Sakuma J, Hayashi S, Abe K, Saito I, Harada S, Sakatani M, Yamamoto S, Matsumoto N, Kaneda Y, and et al. A histologically distinctive interstitial pneumonia induced by overexpression of the interleukin 6, transforming growth factor beta 1, or platelet-derived growth factor B gene. Proc Natl Acad Sci U S A 92: 9570-9574, 1995.